UNCY
Unicycive Therapeutics Inc
NASDAQ: UNCY · HEALTHCARE · BIOTECHNOLOGY
$7.95
-6.86% today
Updated 2026-06-05
Market cap
$156.96M
P/E ratio
—
P/S ratio
23.75x
EPS (TTM)
$-2.25
Dividend yield
—
52W range
$4 – $9
Volume
1.5M
WallStSmart proprietary scores
21
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.0
Quality
B3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
-3.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →205 stocks currently score above 75
Price targets
Analyst target
$39.54
+397.36%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy8 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.02x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -3.73 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-6.25M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $951000.00 | $675000.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-18.06M | $-30.54M | $-36.73M | $-26.55M | $-12.82M |
| EPS | — | — | — | — | $-2.25 |
| Free cash flow | $-15.65M | $-18.30M | $-28.65M | $-31.34M | $-6.25M |
| Profit margin | -1,899.47% | -4,525.04% | — | — | — |
Peer comparison
Smart narrative
Unicycive Therapeutics Inc trades at $7.95. Our Smart Value Score of 21/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -3.73, it sits in the distress.
Frequently asked questions
What is Unicycive Therapeutics Inc's stock price?
Unicycive Therapeutics Inc (UNCY) trades at $7.95, on a P/S of 23.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Unicycive Therapeutics Inc overvalued?
Unicycive Therapeutics Inc carries a Smart Value Score of 21/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Unicycive Therapeutics Inc (UNCY)?
The 12-month analyst consensus target is $39.54, about 397.4% above the current $7.95. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Unicycive Therapeutics Inc's Altman Z-Score is -3.73, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio23.75x
ROE-105.95%
Beta1.79
50D MA$7.44
200D MA$6.27
Shares out0.03B
Float0.02B
Short ratio—
Avg volume1.5M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—